We are an emerging leader with new solutions in the field of nuclear medicine technology

Our innovative products and technologies are designed to meet current and future demands for medical radioisotopes. They mark a new era for nuclear medicine technology.

Discover our Products

Supply

Medical radioisotopes are critical to meet patient healthcare needs and advance clinical research. We’ve charted the course for producing a stable, reliable and domestically sourced isotope supply.

Explore our Processes

Commitment

Our people drive our solutions. From providing domestic supply of isotopes for patients to national security and environmental sustainability, we are committed to advancing radioisotope technology to shape a better world.

Learn More

About NorthStar

We are a nuclear medicine technology company committed to providing the United States with stable, domestic and environmentally friendly radioisotope supply solutions to meet the needs of patients and advance clinical research. Our innovative technologies have the ability to fundamentally transform the ways that medical radioisotopes are produced and distributed around the world.

Learn More About NorthStar

Inside NorthStar

October 1, 2018

U.S. Department of Energy’s National Nuclear Security Administration Honors NorthStar Medical Radioisotopes as First U.S. Producer of Medical Radioisotope Molybdenum-99 in Nearly 30 Years

– Award for Outstanding Achievement presented at 2018 Molybdenum-99 Topical Meeting – Beloit, Wis., October 1, 2018 – NorthStar Medical Radioisotopes, LLC, a company involved in the production and distribution of radioisotopes used for medical imaging, today announced that it received an Award for Outstanding Achievement from the U.S.

Press Releases

July 24, 2018

NorthStar Medical Radioisotopes Announces FDA Approval of Beloit, Wis. Facility for RadioGenix™ System Manufacturing and Provides Update on Commercial Launch Status

– Approval enables expanded manufacturing capacity and supports commercial launch of RadioGenix Systems to produce critically important diagnostic imaging radioisotope technetium-99m from domestic, non-uranium based molybdenum-99 – BELOIT, Wis.

Press Releases

June 18, 2018

NorthStar Medical Technologies Updates Progress on Actinium-225 Radioisotope Program

BELOIT, Wis. – June 18, 2018 – NorthStar Medical Technologies (NorthStar), a company involved in the development, production and distribution of radioisotopes for medical imaging and therapeutics, today provided a progress update on its actinium-225 (Ac-225) radioisotope program.

We are an emerging leader with new solutions in the field of nuclear medicine technology

About NorthStar

How Can We Help?